20 completed, 19 recruiting, 5 active not recruiting, 4 terminated. 34 Phase 2, 26 Phase 1, 3 Not applicable, 2 Phase 3.
Follow 5-Azacitidine: new trials by email Literature Review of 5-Azacitidine trials Research Report on 5-Azacitidine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 122 | 2027-01-15 | 2026-10-07 |
| Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) Azacitidine, Bone Marrow Aspiration and Biopsy, Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 184 | 2027-01-04 | 2026-10-01 |
| Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma Azacitidine, Belinostat, Biospecimen Collection - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 40 | 2027-01-03 | 2026-07-09 |
| FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 TCR/CD8ab-expressing T-cells, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 9 | 2026-10-15 | 2026-09-17 |
| Smart AFO and 5-Azacitidine to Enhance Mobility in Children With Cerebral Palsy Smart Ankle-Foot Orthosis, 5-Azacitidine, Placebo - Cerebral Palsy | Phase 2 | Recruiting | Shirley Ryan AbilityLab | 60 | 2026-05-28 | 2026-06-01 |
| tSCS and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral Palsy tSCS, 5-Azacitidine, Mannitol - Cerebral Palsy | Phase 2 | Recruiting | Shirley Ryan AbilityLab | 80 | 2026-05-28 | 2026-05-29 |
| Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia | Phase 1 | Recruiting | OHSU Knight Cancer Institute | 40 | 2026-04-21 | 2026-10-05 |
| Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms Pacritinib, Decitabine, Decitabine and Cedazuridine - Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm | Phase 2 | Recruiting | University of Washington | 27 | 2026-03-02 | 2026-08-19 |
| Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent Azacitidine, Olutasidenib - Acute Myeloid Leukemia | Phase 2 | Recruiting | University of California, Davis | 28 | 2025-12-17 | 2026-10-27 |
| A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 12 | 2025-07-30 | 2026-09-29 |
| Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Myelodysplastic Syndrome/Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 | Suspended | City of Hope Medical Center | 20 | 2025-04-25 | 2026-10-20 |
| Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Recruiting | City of Hope Medical Center | 43 | 2025-01-28 | 2026-07-16 |
| Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Monocytic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | OHSU Knight Cancer Institute | 40 | 2025-01-03 | 2026-09-16 |
| Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 1 | Suspended | National Cancer Institute (NCI) | 45 | 2024-12-18 | 2026-08-25 |
| Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 147 | 2024-09-27 | 2026-10-28 |
| Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 335 | 2024-09-25 | 2026-10-27 |
| Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 153 | 2024-09-13 | 2026-10-28 |
| Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia Azacitidine, Biospecimen Collection, Bone Marrow Biopsy - Acute Myeloid Leukemia, Myelodysplastic Syndrome/Acute Myeloid Leukemia | Phase 1 | Recruiting | OHSU Knight Cancer Institute | 30 | 2024-08-22 | 2026-06-30 |
| Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia Axatilimab, Azacitidine, Biospecimen Collection - Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Uma Borate | 49 | 2024-08-02 | 2026-08-27 |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2000 | 2024-06-18 | 2026-10-27 |
Showing 20 of 56. Sign in to see all of them.
Leukemia, Myeloid, Acute (34) · Myelodysplastic Syndromes (19) · Leukemia, Myelomonocytic, Chronic (7) · Leukemia (5) · GATA2 Deficiency (4) · Myeloproliferative Disorders (3) · Anemia, Refractory, with Excess of Blasts (2) · Cerebral Palsy (2) · Leukemia, Biphenotypic, Acute (2) · Leukemia, Erythroblastic, Acute (2) · Leukemia, Megakaryoblastic, Acute (2) · Leukemia, Monocytic, Acute (2) · Lymphoma, T-Cell (2) · Recurrence (2) · Anemia, Refractory (1)
National Cancer Institute (NCI) (16) · M.D. Anderson Cancer Center (6) · City of Hope Medical Center (4) · OHSU Knight Cancer Institute (3) · Shirley Ryan AbilityLab (2) · Zhujiang Hospital (2) · Ascentage Pharma Group Inc. (1) · Daiichi Sankyo (1) · Fred Hutchinson Cancer Center (1) · GlaxoSmithKline (1) · Grupo Cooperativo de HemopatÃas Malignas (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Heinrich-Heine University, Duesseldorf (1) · Hetty Carraway (1) · Icahn School of Medicine at Mount Sinai (1)
United States (48) · Canada (7) · Puerto Rico (5) · China (2) · Australia (1) · Germany (1) · Hong Kong (1) · Japan (1) · Mexico (1) · Russia (1) · Singapore (1) · Sweden (1)
Curtis A Lachowiez (2) · Richard E. Champlin, MD, BS (2) · Amanda Blackmon (1) · Amer M Zeidan (1) · Anna Halpern, MD (1) · Annie P Im (1) · Arun Jayaraman, PhD (1) · Brian Jonas, MD (1) · Christina Poh (1) · Courtney DiNardo, MD (1) · Edward D Ball, MD (1) · Ehab L Atallah (1) · Enrica Marchi, M.D., PhD (1) · Francesco Mazziotta, MD, PhD (1)
PMID 23907406, PMID 24092933, PMID 24534108, PMID 24583822, PMID 27795561, PMID 29618479, PMID 33170934, PMID 36902217, PMID 38867582, PMID 39030997, PMID 39290981, PMID 42007254
P30CA033572 (4), U10CA180888 (4), U10CA180820 (3), P30CA006973 (2), U10CA032102 (2), N01CM00038 (1), N01CM00099 (1), N01CM17103 (1), N01CM62204 (1), N01CM62205 (1), P01CA018029 (1), P30CA013330 (1), P30CA093373 (1), U01CA070095 (1), U01CA099168 (1)